XML 68 R51.htm IDEA: XBRL DOCUMENT v3.25.0.1
Licenses, Asset Acquisitions and Contingent Consideration - Schedule of IPR&D Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Acquired Finite-Lived Intangible Assets [Line Items]      
Total in process research and development $ 0 $ 10,000 $ 65
Seralutinib      
Acquired Finite-Lived Intangible Assets [Line Items]      
Total in process research and development 0 10,000 0
Terminated programs      
Acquired Finite-Lived Intangible Assets [Line Items]      
Total in process research and development $ 0 $ 0 $ 65